Charles River to Acquire Frontage's Bioanalysis Businesses
Charles River agreed to acquire Frontage's clinical bioanalysis and DMPK operations in Pennsylvania for $470 million, aiming to enhance its drug development support and long-term growth.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed